China’s high hepatitis prevalence could be a boon for genomic tests developers for early screening of liver cancer

• The country, a global hotspot for liver diseases, has emerged as an attractive target market for developers of genomic liver cancer screening tests
• China accounts for a quarter of the world’s chronic hepatitis B infections and half the liver cancer-related cases